Ipamorelin Research Evidence
The Ipamorelin evidence base: trials, journals, and what the data does not yet show.
Key Findings at a Glance
• Ipamorelin is called the first truly selective growth hormone secretagogue because it stimulates GH release without measurably raising cortisol, prolactin, or ACTH at therapeutic doses. • Unlike most GHRPs, Ipamorelin preserves the natural pulsatile rhythm of growth hormone release rather than forcing a continuous elevation, maintaining normal feedback regulation. • Ipamorelin has only a handful of human studies, primarily pharmacokinetic trials and a discontinued Phase II for postoperative ileus, making its widespread popularity largely based on animal data. • In glucocorticoid-treated rats mimicking osteoporosis, Ipamorelin counteracted steroid-induced bone loss by enhancing bone formation without changing bone mineral density markers.
Body Composition Effects
Research in animal models and preliminary human studies indicates Ipamorelin may influence body composition through GH-mediated pathways including enhanced lipolysis (fat breakdown), increased lean body mass, and improved fat-free mass to fat mass ratios. Studies have documented potential effects on visceral adipose tissue (belly fat), subcutaneous fat distribution, and skeletal muscle protein synthesis. The peptide has been investigated for applications in obesity research, sarcopenia (age-related muscle loss) studies, and metabolic syndrome investigations. Long-term administration studies in animals suggest sustained improvements in body composition metrics without significant adverse effects.
Bone Density Research
Studies suggest Ipamorelin may positively influence bone metabolism through mechanisms involving growth hormone and IGF-1 elevation,. While GH and IGF-1 positively influence bone metabolism, the direct effect of Ipamorelin on bones is less studied. Research in animal models has documented increased longitudinal bone growth in young subjects and increased bone mineral content (BMC) due to increased volume of bone, though bone mineral density itself remained unchanged. Note: No significant changes in bone turnover markers (osteocalcin and bone-specific alkaline phosphatase) were observed in studies,. The peptide was studied in an osteoporosis-mimicking model (glucocorticoid-induced bone loss in adult rats), where it enhanced bone formation. Studies show Ipamorelin causes pulsatile GH release (not sustained elevation), indicating it may preserve normal feedback regulation while potentially supporting bone remodeling processes.
Sleep and Recovery Research
The relationship between growth hormone secretion and sleep quality is well-established in endocrinology research, as natural GH release peaks during slow-wave (deep) sleep. Since Ipamorelin stimulates pulsatile GH release that mimics natural patterns, researchers have hypothesized potential benefits for sleep architecture. However, direct studies specifically evaluating Ipamorelin's effects on sleep quality metrics are limited. Any observed sleep-related effects would theoretically be mediated through GH pathway activation rather than direct CNS effects. Further research is needed to establish whether Ipamorelin administration influences sleep architecture, recovery processes, or subjective sleep quality in controlled settings.
Trials and reviews
- ghrelin agonist metaJCEM2015
consistent IGF-1 + body comp · review
- Frieboes adolescent insomniacsJCEM2003
improved sleep continuity · N=13
- Raun pharmacology studyEur J Endocrinol1998
GH pulse + IGF-1 rise · animal pharmacology, not a human trial
References
- Ipamorelin, the first selective growth hormone secretagogue · Raun K, et al. · 1998
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
- Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
- Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561. · Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW · 1998
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. · Gobburu JV, Agersø H, Jusko WJ et al. · 1999
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. · Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H · 1999
- Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. · Semenistaya E, Zvereva I, Thomas A et al. · 2015
- Svensson J, et al. Effects of growth hormone secretagogues on bone. Endocrine. 2001;14(1):63-66. · Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM · 2001
- A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography. · Timms M, Hall N, Levina V et al. · 2014
- Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a ... · Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C · 2012
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Journal of Gastrointestinal Surgery. 2008;12(7):1223-1231. · Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E · 2007